China Asia Program Lead – Early Phase (e-CAPL)

The China Asia Program Lead – Early Phase (e-CAPL) is a scientific and clinical leader within Development, accountable for leading the China Asia Clinical Development Team – Early Phase (e-CADT) to advance early-phase assets through first-in-human to early proof of concept studies. Guided by Takeda’s values, this role ensures early clinical development decisions are grounded in strong science, patient focus, and ethical standards. In partnership with Global Program Leads and cross-functional stakeholders, the e-CAPL shapes and executes China-specific early development strategies aligned with global objectives. The role contributes critical clinical, translational, and scientific insights to enterprise portfolio decision-making, enabling timely, high-quality go/no-go decisions and maximizing the probability of success for early pipeline assets.